Tracking immune changes in melanoma patients on immunotherapy
Part of Cancer, Skin clinical trials.
This trial studies how your immune system “profiles” change while you’re treated with immunotherapy for melanoma. Results may help doctors better understand who benefits from treatment and when.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have melanoma that has either been fully removed (stage III/IV) or cannot be fully removed (stage IIIC/D or IV).
- You are currently being treated with immunotherapy, such as pembrolizumab or nivolumab, or another immune checkpoint inhibitor.
- If your melanoma cannot be fully removed, your treatment plan must include both immunotherapy and radiotherapy (radiation).
- You can and do sign consent to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This study looks at serial (repeated) tumour biopsies and blood samples in people with advanced melanoma. The goal is to understand biomarkers and disease changes over time, which may help improve future treatment decisions.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This study looks for lab and tumor features that may help predict who benefits from follow-up (adjuvant) immunotherapy after surgery for melanoma. Your past treatment and tumor samples may be used to improve future treatment decisions.
This trial studies how the immune system and body metabolism change in people with in-transit melanoma (melanoma spread to nearby skin). It aims to understand what’s happening in these lesions and how that information could guide better treatment.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.